(Q37690567)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20147902%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

review article

1 reference

title

Breast and prostate cancer: more similar than different (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20147902%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

1 reference

Gail Petuna Risbridger

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20147902%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Wayne D Tilley

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20147902%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

author name string

Ian D Davis

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20147902%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Stephen N Birrell

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20147902%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

language of work or name

English

0 references

publication date

11 February 2010

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20147902%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

published in

Nature Reviews Cancer

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20147902%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

volume

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20147902%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20147902%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

page(s)

205-212

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20147902%20AND%20SRC:MED&resulttype=core&format=json

Progesterone and breast cancer.

18 January 2020

cites work

1 reference

Macrophages induce invasiveness of epithelial cancer cells via NF-kappa B and JNK.

21 January 2018

1 reference

Interleukin-8 is a paracrine inducer of fibroblast growth factor 2, a stromal and epithelial growth factor in benign prostatic hyperplasia

21 January 2018

1 reference

IL-4 protects tumor cells from anti-CD95 and chemotherapeutic agents via up-regulation of antiapoptotic proteins

21 January 2018

1 reference

Single-therapy androgen suppression in men with advanced prostate cancer: a systematic review and meta-analysis

21 January 2018

1 reference

Prostatic hormonal carcinogenesis is mediated by in situ estrogen production and estrogen receptor alpha signaling.

21 January 2018

1 reference

Toremifene for the prevention of prostate cancer in men with high grade prostatic intraepithelial neoplasia: results of a double-blind, placebo controlled, phase IIB clinical trial

31 March 2020

1 reference

Cloning of a novel receptor expressed in rat prostate and ovary

31 March 2020

1 reference

Essential role for estrogen receptor beta in stromal-epithelial regulation of prostatic hyperplasia.

31 March 2020

1 reference

Treating prostate cancer: a rationale for targeting local oestrogens

31 March 2020

1 reference

Estrogen receptor-beta activated apoptosis in benign hyperplasia and cancer of the prostate is androgen independent and TNFalpha mediated

31 March 2020

1 reference

Androgens induce divergent proliferative responses in human breast cancer cell lines.

31 March 2020

1 reference

Disruption of androgen receptor signaling by synthetic progestins may increase risk of developing breast cancer

31 March 2020

1 reference

Endocrine and intracrine sources of androgens in women: inhibition of breast cancer and other roles of androgens and their precursor dehydroepiandrosterone

31 March 2020

1 reference

Testosterone and the breast

31 March 2020

1 reference

Androgen receptor inhibits estrogen receptor-alpha activity and is prognostic in breast cancer

31 March 2020

1 reference

The dual, opposing roles of estrogen in the prostate.

31 March 2020

1 reference

A physiologic role for testosterone in limiting estrogenic stimulation of the breast

31 March 2020

1 reference

Clinical importance of estrogen receptor-beta evaluation in breast cancer patients treated with adjuvant tamoxifen therapy

31 March 2020

1 reference

Steroid hormone receptor expression in male breast cancer

31 March 2020

1 reference

The evolving role of oestrogen receptor beta in clinical breast cancer

31 March 2020

1 reference

Medroxyprogesterone acetate therapy in advanced breast cancer: the predictive value of androgen receptor expression

31 March 2020

1 reference

Expression of androgen receptors in primary breast cancer

31 March 2020

1 reference

Cooperation of p27(Kip1) and p18(INK4c) in progestin-mediated cell cycle arrest in T-47D breast cancer cells.

31 March 2020

1 reference

DNA replication licensing and progenitor numbers are increased by progesterone in normal human breast

31 March 2020

1 reference

The androgen metabolite 5alpha-androstane-3beta,17beta-diol (3betaAdiol) induces breast cancer growth via estrogen receptor: implications for aromatase inhibitor resistance

31 March 2020

1 reference

Estrogen--the good, the bad, and the unexpected.

31 March 2020

1 reference

The androgen axis in recurrent prostate cancer

31 March 2020

1 reference

Testosterone and dihydrotestosterone tissue levels in recurrent prostate cancer

31 March 2020

1 reference

Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer

31 March 2020

1 reference

Steroidogenesis inhibitors alter but do not eliminate androgen synthesis mechanisms during progression to castration-resistance in LNCaP prostate xenografts

31 March 2020

1 reference

Targeting the androgen receptor: improving outcomes for castration-resistant prostate cancer

31 March 2020

1 reference

History of aromatase: saga of an important biological mediator and therapeutic target

31 March 2020

1 reference

Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven.

31 March 2020

1 reference

CYP17 inhibition as a hormonal strategy for prostate cancer.

31 March 2020

1 reference

The roles of sex steroid receptor coregulators in cancer

31 March 2020

1 reference

Androgen receptor coregulators and their involvement in the development and progression of prostate cancer.

31 March 2020

1 reference

Nuclear receptor coregulators in cancer biology

31 March 2020

1 reference

Identification of CDK10 as an important determinant of resistance to endocrine therapy for breast cancer

31 March 2020

1 reference

Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer

31 March 2020

1 reference

AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer

31 March 2020

1 reference

Expression of SRC-1, AIB1, and PEA3 in HER2 mediated endocrine resistant breast cancer; a predictive role for SRC-1.

31 March 2020

1 reference

Coassociation of estrogen receptor and p160 proteins predicts resistance to endocrine treatment; SRC-1 is an independent predictor of breast cancer recurrence

31 March 2020

1 reference

Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer

31 March 2020

1 reference

SRC-3 is required for prostate cancer cell proliferation and survival

31 March 2020

1 reference

Steroid receptor coactivator-3/AIB1 promotes cell migration and invasiveness through focal adhesion turnover and matrix metalloproteinase expression

31 March 2020

1 reference

E6-associated protein (E6-AP) is a dual function coactivator of steroid hormone receptors

31 March 2020

1 reference

Prostate cancer patients with BRCA2 mutation face poor survival

31 March 2020

1 reference

Associations of high-grade prostate cancer with BRCA1 and BRCA2 founder mutations

31 March 2020

1 reference

Decreased BRCA1 confers tamoxifen resistance in breast cancer cells by altering estrogen receptor-coregulator interactions.

31 March 2020

1 reference

Increase of androgen-induced cell death and androgen receptor transactivation by BRCA1 in prostate cancer cells

31 March 2020

1 reference

BRCA2 cooperates with histone acetyltransferases in androgen receptor-mediated transcription.

31 March 2020

1 reference

Control of androgen receptor signaling in prostate cancer by the cochaperone small glutamine rich tetratricopeptide repeat containing protein alpha

31 March 2020

1 reference

Development of a second-generation antiandrogen for treatment of advanced prostate cancer

31 March 2020

1 reference

Prostate cancer stem cells: a new target for therapy

31 March 2020

1 reference

Clinical use of therapies targeting tumor vasculature and stroma

31 March 2020

1 reference

Prostatic tumor stroma: a key player in cancer progression.

31 March 2020

1 reference

Mesenchymal-epithelial interactions: past, present, and future

31 March 2020

1 reference

Reprint of: Stromogenic prostatic carcinoma pattern (carcinomas with reactive stromal grade 3) in needle biopsies predicts biochemical recurrence-free survival in patients after radical prostatectomy

31 March 2020

1 reference

Minireview: regulation of prostatic stem cells by stromal niche in health and disease.

31 March 2020

1 reference

Molecular characterisation of the tumour microenvironment in breast cancer

31 March 2020

1 reference

Hormonal, cellular, and molecular regulation of normal and neoplastic prostatic development

31 March 2020

1 reference

Androgen-induced programs for prostate epithelial growth and invasion arise in embryogenesis and are reactivated in cancer.

31 March 2020

1 reference

Identification of SFRP1 as a candidate mediator of stromal-to-epithelial signaling in prostate cancer

31 March 2020

1 reference

Identification of molecular distinctions between normal breast-associated fibroblasts and breast cancer-associated fibroblasts

31 March 2020

1 reference

Pten in stromal fibroblasts suppresses mammary epithelial tumours

31 March 2020

1 reference

Macrophage/cancer cell interactions mediate hormone resistance by a nuclear receptor derepression pathway

31 March 2020

1 reference

Cancer immunoediting: from immunosurveillance to tumor escape

31 March 2020

1 reference

Inflammation and breast cancer. Balancing immune response: crosstalk between adaptive and innate immune cells during breast cancer progression

31 March 2020

1 reference

C-reactive protein is significantly associated with prostate-specific antigen and metastatic disease in prostate cancer

31 March 2020

1 reference

The influence of chronic inflammation in prostatic carcinogenesis: a 5-year followup study.

31 March 2020

1 reference

A comprehensive association study for genes in inflammation pathway provides support for their roles in prostate cancer risk in the CAPS study

31 March 2020

1 reference

IL-17 expression by breast-cancer-associated macrophages: IL-17 promotes invasiveness of breast cancer cell lines

31 March 2020

1 reference

A cytokine-mediated link between innate immunity, inflammation, and cancer

31 March 2020

1 reference

Multiple signal transduction pathways mediate interleukin-4-induced 3beta-hydroxysteroid dehydrogenase/Delta5-Delta4 isomerase in normal and tumoral target tissues

31 March 2020

1 reference

Crucial role of cytokines in sex steroid formation in normal and tumoral tissues

31 March 2020

1 reference

Interleukin-6 induces prostate cancer cell growth accompanied by activation of stat3 signaling pathway .

31 March 2020

1 reference

Prostaglandin E(2) stimulates prostatic intraepithelial neoplasia cell growth through activation of the interleukin-6/GP130/STAT-3 signaling pathway

31 March 2020

1 reference

Interleukin-6 undergoes transition from growth inhibitor associated with neuroendocrine differentiation to stimulator accompanied by androgen receptor activation during LNCaP prostate cancer cell progression

31 March 2020

1 reference

IL-6 triggers malignant features in mammospheres from human ductal breast carcinoma and normal mammary gland

31 March 2020

1 reference

Interleukin-4 activates androgen receptor through CBP/p300.

31 March 2020

1 reference

The use of dendritic cells in cancer therapy

31 March 2020

1 reference

Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer

31 March 2020

1 reference

Estrogen as therapy for breast cancer

31 March 2020

1 reference

Adjuvant hormonal therapy for breast cancer and risk of hormone receptor-specific subtypes of contralateral breast cancer

31 March 2020

1 reference

Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941.

31 March 2020

1 reference

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

31 March 2020

1 reference

Scottish adjuvant tamoxifen trial: a randomized study updated to 15 years

31 March 2020

1 reference

An open, randomised, multicentre, phase 3 trial comparing the efficacy of two tamoxifen schedules in preventing gynaecomastia induced by bicalutamide monotherapy in prostate cancer patients.

31 March 2020

1 reference

Toremifene increases bone mineral density in men receiving androgen deprivation therapy for prostate cancer: interim analysis of a multicenter phase 3 clinical study

31 March 2020

1 reference

Toremifene improves lipid profiles in men receiving androgen-deprivation therapy for prostate cancer: interim analysis of a multicenter phase III study

31 March 2020

1 reference

Clinical usefulness of high-dose toremifene in patients relapsed on treatment with an aromatase inhibitor

31 March 2020

1 reference

New selective estrogen and androgen receptor modulators

31 March 2020

1 reference

Randomized trial of tamoxifen alone or combined with fluoxymesterone as adjuvant therapy in postmenopausal women with resected estrogen receptor positive breast cancer. North Central Cancer Treatment Group Trial 89-30-52.

31 March 2020

1 reference

Maximal androgen blockade for advanced prostate cancer

31 March 2020

1 reference

Antiandrogen withdrawal in castrate-refractory prostate cancer: a Southwest Oncology Group trial (SWOG 9426)

31 March 2020

1 reference

Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety upda

31 March 2020

1 reference

Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women

31 March 2020

1 reference

Exemestane: a review of its use in postmenopausal women with breast cancer

31 March 2020

1 reference

American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004.

31 March 2020

1 reference

Selective aromatase inhibition for patients with androgen-independent prostate carcinoma

31 March 2020

1 reference

LHRH agonists for adjuvant therapy of early breast cancer in premenopausal women

31 March 2020

1 reference

The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer

31 March 2020

1 reference

Finasteride for prostatic disease: an updated and comprehensive review

31 March 2020

1 reference

Prostate cancer incidence among finasteride and alpha-blocker users in the Finnish Prostate Cancer Screening Trial

31 March 2020

1 reference

PCPT: Evidence that finasteride reduces risk of most frequently detected intermediate- and high-grade (Gleason score 6 and 7) cancer

31 March 2020

1 reference

Analysis of the androgenic activity of synthetic "progestins" currently used for the treatment of prostate cancer

31 March 2020

1 reference

Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583).

31 March 2020

1 reference

Phase II study of ketoconazole plus granulocyte-macrophage colony-stimulating factor for prostate cancer: effect of extent of disease on outcome

31 March 2020

1 reference

Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points.

31 March 2020

1 reference

CYP17 blockade by abiraterone: further evidence for frequent continued hormone-dependence in castration-resistant prostate cancer

31 March 2020

1 reference

Is abiraterone acetate well tolerated and effective in the treatment of castration-resistant prostate cancer?

31 March 2020

1 reference

Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer

31 March 2020

1 reference

Gene expression profiling of the tumor microenvironment during breast cancer progression

31 March 2020

1 reference

12 December 2020

Nuclear receptor coregulators: cellular and molecular biology

1 reference

12 December 2020

Endocrine-induced regression of cancers

1 reference

12 December 2020

Evaluation of androgen, estrogen (ER alpha and ER beta), and progesterone receptor expression in human prostate cancer by real-time quantitative reverse transcription-polymerase chain reaction assays

1 reference

12 December 2020

Physiological action of progesterone in target tissues

1 reference

12 December 2020

Breast cancer susceptibility gene 1 (BRCAI) is a coactivator of the androgen receptor.

1 reference

12 December 2020

Altered expression of androgen receptor in the malignant epithelium and adjacent stroma is associated with early relapse in prostate cancer

1 reference

12 December 2020

Estrogen and progesterone receptor proteins in breast cancer

1 reference

12 December 2020

The influence of finasteride on the development of prostate cancer

1 reference

12 December 2020

Reactive stroma as a predictor of biochemical-free recurrence in prostate cancer

1 reference

12 December 2020

BRCA2 mutations and androgen receptor expression as independent predictors of outcome of male breast cancer patients.

1 reference

12 December 2020

Progestins regulate genes that can elicit both proliferative and antiproliferative effects in breast cancer cells.

1 reference

12 December 2020

Inhibition of breast cancer tissue aromatase activity and estrogen concentrations by the third-generation aromatase inhibitor vorozole

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRC2795

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20147902%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

1 reference